Showing results (61-70 of 199) with videos related to
Sort By:
Pageof 20
Cancers|October 16, 2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of TreatmentDana Amsterdam, Ori Grossberger, Natan Melamed, et al.Cancers|May 13, 2026
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based CombinationsDor Shpitzer, Chava Perry, Tamir Shragai, et al.Infection|January 22, 2016
Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcomeEmilia Hardak, Irit Avivi, Lina Berkun, et al.Annals of Hematology|June 13, 2019
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective studyRon Ram, Odelia Amit, Tsila Zuckerman, et al.American Journal of Hematology|February 21, 2013
Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab eraIrit Avivi, Ariel Zilberlicht, Eldad J Dann, et al.Journal of Clinical Medicine|February 11, 2023
Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple MyelomaOr Atar, Ron Ram, Irit Avivi, et al.Leukemia & Lymphoma|January 18, 2014
Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?Meirav Kedmi, Irit Avivi, Elena Ribakovsky, et al.Journal of Neuro-Oncology|October 25, 2020
Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patientsNadav Sarid, Felix Bokstein, Deborah T Blumenthal, et al.The Israel Medical Association Journal : IMAJ|May 5, 2017
Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell LymphomaNoa Lavi, Gali Shapira, Ariel Zilberlicht, et al.British Journal of Haematology|December 16, 2014
Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patientsLior Carmon, Irit Avivi, Riva Kovjazin, et al.Pageof 20